Inovio Pharmaceuticals, Inc. (INO) has a consensus analyst rating of Buy, based on 17 analysts covering the stock. Of those, 9 recommend buying, 6 recommend holding, and 2 recommend selling.
The analyst consensus price target for INO is $6.00, representing a +440.5% upside from the current price of $1.11. Price targets range from a low of $6.00 to a high of $6.00.
